Details of the Drug

General Information of Drug (ID: DMTRMBL)

Drug Name
NBI-6024
Synonyms Diabetes therapeutics, Neurocrine/Taisho; APL (diabetes), Neurocrine/Taisho; Applied Peptide Ligand(diabetes), Neurocrine/Taisho; Insulin B9-23 peptide analog, Taisho/Neurocrine
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Discontinued in Phase 2 [1]
Structure
3D MOL 2D MOL
Cross-matching ID
PubChem CID
9812645
UNII
OMF3CT7D4L
DrugBank ID
DB05819
TTD ID
D0B3MX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin (INS) TTZOPHG INS_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type-1 diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin (INS) DTT INS 6.70E-01 -0.12 -0.46
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011773)
2 No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.Diabetes Care.2009 Nov;32(11):2036-40.